Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-21
2002-07-02
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S062000
Reexamination Certificate
active
06413977
ABSTRACT:
FIELD OF THE INVENTION
This invention is directed to novel ligands for dopamine receptors. More particularly, the present invention is directed to optionally substituted 1,2,3,11b-tetrahydrochromeno[4,3,2-de]isoquinoline compounds and their use in pharmaceutical formulations for treatment of dopamine-related dysfunction of the central and peripheral nervous system.
BACKGROUND AND SUMMARY OF THE INVENTION
Dopamine, a neurotransmitter in the central nervous system, has been implicated in numerous neurological disorders. For example, it has been hypothesized that excess stimulation of dopamine receptor subtypes may be linked to schizophrenia. Additionally, it is generally recognized that either excessive or insufficient functional dopaminergic activity in the central and/or peripheral nervous system may cause hypertension, narcolepsy, and other behavioral, neurological, physiological, and movement disorders including Parkinson's disease, a chronic, progressive disease characterized by an inability to control the voluntary motor system.
Dopamine receptors have traditionally been classified into two families (the D
1
and D
2
dopamine receptor families) based on pharmacological and functional evidence. D
1
receptors preferentially recognize the phenyltetrahydrobenzazepines and generally lead to stimulation of the enzyme adenylate cyclase, whereas D
2
receptors recognize the butyrophenones and benzamides and often are coupled negatively (or not at all) to adenylate cyclase. It is now known that at least five genes exist that code for subtypes of dopamine receptors: the D
1
, D
2
, D
3
, D
4
and D
5
receptor subtypes. The traditional classification, however, remains useful, with the D
1
-like class comprising the D
1
(D
1A
) and the D
5
(D
1B
) receptor subtypes, whereas the D
2
-like class consists of the D
2
, D
3
and D
4
receptor subtypes. Variation can occur also through splice variants (e.g., the D
2L
and D
2S
splice variants), as well as through different alleles (e.g., multiple repeats of the D
4
gene).
Central nervous system drugs exhibiting affinity for the dopamine receptors are generally classified not only by their receptor selectivity, but further by their agonist (receptor activating) or antagonist (receptor blocking) activity. While the physiological activities associated with the interaction of dopamine with the various receptor subtypes are not fully understood, it is known that ligands exhibiting selectivity for a particular receptor subtype will produce more or less predicable neuropharmacological results. The availability of selective dopamine receptor antagonist and agonist compounds permits the design of experiments to enhance understanding of the many functional roles of D
1
receptors and can lead to new treatments for various central and peripheral nervous system disorders. In addition, if agonists were available with high affinity for both the D
1
and D
2
receptors, these agonists could be used under circumstances where binding to both D
1
and D
2
receptors is beneficial.
The early focus of dopamine receptor studies was on the D
2
family, but a critical role of the dopamine D
1
receptor in nervous system function has become apparent recently. That early work on selective D
1
receptor ligands primarily focused on molecules from a single chemical class, the phenyltetrahydrobenzazepines, such as the antagonist SCH23390 (1):
Several of the phenyltetrahydrobenzazepines were found to be D
1
receptor agonists; however, the agonists derived from this class [including, for example, SKF38393 (+)-2] generally were partial agonists. Even SKF82958, purported to be a full agonist, recently has been shown not to have full intrinsic efficacy in preparations with decreased receptor reserve. The differentiation between D
1
agonists of full and partial efficacy is important to the medical research community because this may influence the actions of these compounds on complex central nervous system mediated events. For example, two full agonists (dihydrexidine and A-77636) have exceptional antiparkinsonian effects in the MPTP-treated monkey model, whereas partial agonists are without significant activity. More recent data suggest that full and partial agonists also differ in their effects on other complex neural functions. In addition, there are receptor-mediated events (e.g., recruitment of G proteins and associated receptor kinases) that can affect agonist activity. These latter biochemical events may occur independently of the changes in second messenger levels (e.g., cAMP) mediated by a drug.
Accordingly, researchers have directed their efforts to design ligands that are full agonists (i.e., have full intrinsic efficacy) for the D
1
receptor. One such compound is dihydrexidine (3), a hexahydrobenzo[&agr;]phenanthridine of the formula:
The structure of dihydrexidine (3) is unique from other D
1
agonists because the accessory ring system is tethered, making the molecule relatively rigid. Molecular modeling studies of dihydrexidine (3) have shown that the compound has a limited number of low energy conformations, and the aromatic rings are held in a relatively coplanar arrangement in all of these conformations. The recent elucidation of the configuration of the active enantiomer of dihydrexidine (3) was consistent with predictions from this model.
Unlike other high affinity, high intrinsic activity D
1
agonists like 3-substituted aminomethylisochromans, dihydrexidine (3) provided a semi-rigid template for developing a dopamine ligand model. The essential features of this model include the presence of a transoid &bgr;-phenyldopamine moiety, an equatorially oriented electron lone pair on the basic nitrogen atom, and near coplanarity of the pendant phenyl ring with the catechol ring. The dihydrexidine-based model has a transoid &bgr;-phenyldopamine moiety, whereas the dopaminergic phenyltetrahydrobenzazepines have a cisoid &bgr;-phenyldopamine conformation. The dihydrexidine-based model has served as the basis for the design of additional D
1
receptor agonists. The design and synthesis of D
1
receptor agonists having high intrinsic activity is important to the medical research community due to the potential use of full agonists to treat complex central nervous system mediated events, and also conditions in which peripheral dopamine receptors are involved. For example, the compositions of the present invention have potential use as agents for lowering blood pressure, and for affecting lung and kidney function.
One embodiment of the present invention is a novel class of dopamine receptor agonists of the general formula:
and pharmaceutically acceptable salts thereof, and pharmaceutical formulations of such compounds. The present compounds are useful for treating patients having a dopamine-related dysfunction of the central nervous system (as evidenced by an apparent neurological, psychological, physiological, or behavioral disorder), as well as conditions in which peripheral dopamine receptors are involved (including target tissues such as the kidney, lung, endocrine, and cardiovascular systems).
REFERENCES:
patent: 25 29 580 (1976-02-01), None
patent: 2105 323 (1982-06-01), None
patent: 9911649 (1999-03-01), None
Grubbs Russell A.
Mailman Richard B.
Nichols David E.
Barnes & Thornburg
Purdue Research Foundation
Robinson Binta
Rotman Alan L.
LandOfFree
Chromeno[4,3,2-DE]isoquinolines as potent dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromeno[4,3,2-DE]isoquinolines as potent dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromeno[4,3,2-DE]isoquinolines as potent dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2853108